Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 79.67 -0.86 (-1.07%) Market Cap: 15.12 Bil Enterprise Value: 15.17 Bil PE Ratio: 74.44 PB Ratio: 2.98 GF Score: 76/100

Biomarin Pharmaceutical Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 10:40PM GMT
Release Date Price: $94.75 (+0.92%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Welcome to the second day of the BofA Healthcare Conference. My name is Geoff Meacham the senior biopharma analyst, and we're thrilled today to have BioMarin on stage and with me is Brian Mueller, CFO. Brian, welcome.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - CFO & Executive VP

Thank you, Geoff. Hi, everybody.

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

So a tick to you just to say a couple of things like post the quarter, high level, and then we're getting some questions.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - CFO & Executive VP

Yes, I appreciate it. Thanks. Everyone. Thanks again for having us. Great to participate in the conference. We at BioMarin are pleased to be executing on our strategy here in the early parts of 2023, which include leveraging our profitable and growing base business of mostly enzyme-based products

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot